Diamedica Therapeutics Stock Performance
DMAC Stock | USD 2.77 0.12 4.53% |
The firm shows a Beta (market volatility) of 1.35, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DiaMedica Therapeutics will likely underperform. DiaMedica Therapeutics right now shows a risk of 3.12%. Please confirm DiaMedica Therapeutics mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if DiaMedica Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Low | High |
Very Weak
Over the last 90 days DiaMedica Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, DiaMedica Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.57) | Five Day Return (0.75) | Year To Date Return (6.36) | Ten Year Return (84.99) | All Time Return (89.80) |
Last Split Factor 1:20 | Dividend Date 2018-11-15 | Last Split Date 2018-11-15 |
1 | Acquisition by James Parsons of 21428 shares of DiaMedica Therapeutics subject to Rule 16b-3 | 01/02/2024 |
2 | DiaMedica Therapeutics names Masuoka as its chief medical officer | 01/22/2024 |
3 | DiaMedica Therapeutics Inc. Sees Significant Growth in Short Interest - MarketBeat | 02/01/2024 |
4 | Do Traders Think DiaMedica Therapeutics Inc Can Keep Climbing Wednesday - InvestorsObserver | 02/28/2024 |
5 | DMAC Stock Earnings DiaMedica Therapeutics Meets EPS for Q4 2023 | 03/20/2024 |
6 | DiaMedica Therapeutics Inc.s Path To Profitability | 03/21/2024 |
7 | Acquisition by James Parsons of 16773 shares of DiaMedica Therapeutics at 3.58 subject to Rule 16b-3 | 03/27/2024 |
Begin Period Cash Flow | 4.7 M | |
Free Cash Flow | -18.8 M |
DiaMedica |
DiaMedica Therapeutics Relative Risk vs. Return Landscape
If you would invest 284.00 in DiaMedica Therapeutics on December 29, 2023 and sell it today you would lose (7.00) from holding DiaMedica Therapeutics or give up 2.46% of portfolio value over 90 days. DiaMedica Therapeutics is currently generating 0.0075% in daily expected returns and assumes 3.1242% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than DiaMedica, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
DiaMedica Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DiaMedica Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DiaMedica Therapeutics, and traders can use it to determine the average amount a DiaMedica Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0024
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | DMAC |
Estimated Market Risk
3.12 actual daily | 27 73% of assets are more volatile |
Expected Return
0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average DiaMedica Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DiaMedica Therapeutics by adding DiaMedica Therapeutics to a well-diversified portfolio.
DiaMedica Therapeutics Fundamentals Growth
DiaMedica Stock prices reflect investors' perceptions of the future prospects and financial health of DiaMedica Therapeutics, and DiaMedica Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DiaMedica Stock performance.
Return On Equity | -0.47 | ||||
Return On Asset | -0.3 | ||||
Current Valuation | 50.75 M | ||||
Shares Outstanding | 37.96 M | ||||
Price To Earning | (3.52) X | ||||
Price To Book | 2.02 X | ||||
EBITDA | (21.24 M) | ||||
Net Income | (19.38 M) | ||||
Cash Per Share | 1.45 X | ||||
Current Ratio | 25.50 X | ||||
Cash Flow From Operations | (18.73 M) | ||||
Earnings Per Share | (0.60) X | ||||
Total Asset | 54.16 M | ||||
Retained Earnings | (115.56 M) | ||||
Current Asset | 5.24 M | ||||
About DiaMedica Therapeutics Performance
To evaluate DiaMedica Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when DiaMedica Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare DiaMedica Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand DiaMedica Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents DiaMedica's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.41) | (0.43) | |
Return On Assets | (0.36) | (0.38) | |
Return On Equity | (0.38) | (0.40) |
Things to note about DiaMedica Therapeutics performance evaluation
Checking the ongoing alerts about DiaMedica Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DiaMedica Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.DiaMedica Therapeutics had very high historical volatility over the last 90 days | |
Net Loss for the year was (19.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 27.0% of the company shares are held by company insiders | |
Latest headline from MacroaxisInsider: Acquisition by James Parsons of 16773 shares of DiaMedica Therapeutics at 3.58 subject to Rule 16b-3 |
- Analyzing DiaMedica Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DiaMedica Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining DiaMedica Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DiaMedica Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DiaMedica Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DiaMedica Therapeutics' stock. These opinions can provide insight into DiaMedica Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Return On Assets (0.30) | Return On Equity (0.47) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.